Summary of Product Characteristics (SmPC) - Campral EC
1 NAME OF THE MEDICINAL PRODUCT
Campral EC
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 333 mg acamprosate calcium, equivalent to 300 mg of acamprosate.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Enterocoated tablets.
Campral tablets are white and round with ‘333’ engraved on one side and approximately 10 mm in diameter.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Acamprosate is indicated as therapy to “maintain abstinence in alcohol-dependent patients”. It should be combined with counselling.
4.2 Posology and method of administration
Posology
Adults within the age range 18-65 years:
- 2 tablets three times daily with meals (2 tablets morning, noon and night) in subjects weighing 60kg or more.
- In subjects weighing less than 60kg, 4 tablets divided into three daily doses with meals (2 tablets in the morning, 1 at noon and 1 at night).
Older people
Acamprosate should not be used in older people
Paediatric population
Acamprosate should not be used in children
The recommended treatment period is one year. Treatment with acamprosate should be initiated as soon as possible after the withdrawal period and should be maintained if the patient relapses.
Acamprosate does not prevent the harmful effects of continuous alcohol abuse. Continued alcohol abuse negates the therapeutic benefit, therefore acamprosate treatment should only be initiated after weaning therapy, once the patient is abstinent from alcohol.
4.3 Contraindications
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
- Lactating women (see section 4.6)
- In cases of renal insufficiency (serum creatinine >120 micromol/L)
4.4 Special warnings and precautions for use
The safety and efficacy of Campral has not been established in patients younger than 18 years or older than 65 years. Campral is therefore not recommended for use in these populations.
The safety and efficacy of Campral has not been established in patients with severe liver insufficiency (Childs-Pugh Classification C).
Because the interrelationship between alcohol dependence, depression and suicidality is well- recognised and complex, it is recommended that alcohol-dependent patients, including those treated with acamprosate, be monitored for such symptoms.
Excipients:
This medicine contains less than 1mmol sodium (23mg) per dosage unit, that is to say it is essentially ‘sodium free’
Abuse and dependence
Non-clinical studies suggest that acamprosate has little or no abuse potential. No evidence of dependence on acamprosate was found in any clinical study thus demonstrating that acamprosate has no significant dependence potential.
4.5 Interaction with other medicinal products and other forms of interaction
The concomitant intake of alcohol and acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate. Administering acamprosate with food diminishes the bioavailability of the drug compared with its administration in the fasting state.
In clinical trials, acamprosate has been safely administered in combination with antidepressants, anxiolytics, hypnotics and sedatives, and non-opioid analgesics
Pharmacokinetic studies have been completed and show no interaction between acamprosate and diazepam, disulfiram, oxazepam, tetrabamate, meprobamate or imipramine.
There is no information available on the concomitant administration of acamprosate with diuretics.
4.6 Fertility, Pregnancy and lactation
Pregnancy
There is no adequate data from the use of Campral in pregnant women. Animal studies do not indicate any evidence of foetotoxicity or tetragenicity. Campral must therefore only be used during pregnancy after a careful benefit/risk assessment, when the patient cannot abstain from drinking alcohol without being treated with acamprosate and when there is consequently a risk of foetotoxicity or teratogenicity due to alcohol.
Breast-feeding
It is known that Campral is excreted in the milk of lactating animals. It is not known whether acamprosate is excreted in human milk. There are no adequate data from the use of acamprosate in infants. Campral must therefore not be used in breastfeeding women.
If a breastfeeding woman cannot abstain from drinking alcohol without being treated with acamprosate, a decision must be made whether to discontinue nursing or to discontinue Campral, taking into account the importance of the medicinal product to the woman.
Fertility
In animal studies, no adverse effects on fertility were observed. Whether or not acamprosate affects the fertility in humans is unknown.
4.7 Effects on ability to drive and use machines
Campral has no influence on the ability to drive and use machines.
4.8 Undesirable effects
According to information collected during clinical trials and spontaneous reports since marketing authorization, the following adverse reactions may occur under treatment with Campral.
The following definitions apply to the frequency terminology used hereafter: very common (≥1/10), common (≥ 1/100, < 1/10), uncommon (≥1/1,000, < 1/100), rare
(≥1/10,000, < 1/1,000), very rare (< 1/10,000, including isolated cases), frequency not known (cannot be estimated from the available data)
Gastrointestinal
disorders: Very
common: Diarrhoea
Common: Abdominal pain, nausea, vomiting, flatulence
Skin and subcutaneous tissue
disorders: Common: Pruritus,
maculo-papular rash Not
known: Vesiculo-bullous
eruptions
Immune system disorders:
Very rare: Hypersensitivity reactions including urticaria, angio-oedema or anaphylactic reactions.
Reproductive system and breast
disorders: Common: Frigidity or
impotence.
Psychiatric disorders:
Common: Decreased
libido Uncommon:
Increased libido
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
Acute overdose is usually mild. In the reported cases, the only symptom, which can be reasonably related to overdose is diarrhoea. No case of hypercalcaemia has ever been reported. Treatment of overdose is directed to symptoms.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Acamprosate (calcium acetylhomotaurinate) has a chemical structure similar to that of amino-acid neuromediators, such as taurine or gamma-amino-butyric acid (GABA), including an acetylation to permit passage across the blood brain barrier. Acamprosate may act by stimulating GABAergic inhibitory neurotransmission and antagonising excitatory amino-acids, particularly glutamate.
Animal experimental studies have demonstrated that acamprosate affects alcohol dependence in rats, decreasing the voluntary intake of alcohol without affecting food and total fluid intake.
5.2 Pharmacokinetic properties
Acamprosate absorption across the gastrointestinal tract is moderate, slow and sustained and varies substantially from person to person. Food reduces the oral absorption of acamprosate. Steady state levels of acamprosate are achieved by the seventh day of dosing. Acamprosate is not protein bound.
Oral absorption shows considerable variability and is usually less than 10% of the ingested drug in the first 24 hours. The drug is excreted in the urine and is not metabolised significantly. There is a linear relationship between creatinine clearance values and total apparent plasma clearance, renal clearance and plasma half-life of acamprosate.
The kinetics of acamprosate are not modified in group A or B of the Child-Pugh classification of impaired liver function, a population which is likely to be part of the target population for acamprosate. This is in accordance with the absence of hepatic metabolism of the drug.
5.3 Preclinical safety data
In the preclinical studies, signs of toxicity are related to the excessive intake of calcium and not to acetylhomotaurine. Disorders of phosphorus/calcium metabolism have been observed including diarrhoea, soft tissue calcification, renal and cardiac lesions. Acamprosate had no mutagenic or carcinogenic effect, nor any teratogenic or adverse effects on the male or female reproductive systems of animals. Detailed in vitro and in vivo research on acamprosate to detect genetic and chromosomal mutations has not produced any evidence of potential genetic toxicity.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Crospovidone (KOLLIDON CL)
Microcrystalline cellulose (AVICEL PH 101)
Magnesium silicate (COMPRESSIL)
Sodium starch glycolate (EXPLOTAB)
Anhydrous colloidal silica (AEROSIL 200)
Magnesium stearate
Anionic copolymer of metacrylic acid and acrylic acid ethyl ester (EUDRAGIT L 30 D)
Talc
Propylene glycol
6.2 Incompatibilities
Not applicable
6.3 Shelf life
3 years.
6.4 Special precautions for storage
This medicinal product does not require any special storage conditions
6.5 Nature and contents of container
PVC/PVDC aluminium sheets of blisters containing 12 or 20 tablets. Sheets of blisters are presented in cartons of 60, 84, 168 or 200 tablets.
Polypropylene bottles of 125 ml capacity, closed with tamper-evident polypropylene cap, containing 180 tablets.
6.6 Special precautions for disposal
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
Merck Serono Limited
5 New Square
Bedfont Lakes Business Park
Feltham
Middlesex
TW14 8HA
UK
8 MARKETING AUTHORISATION NUMBER(S)
PL 11648/0289
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
18 December 1995 (first authorization)
10 DATE OF REVISION OF THE TEXT
05/08/2026